Brian Leyland‐Jones

Avera Health

Full Professor(heuristic)

HER2/EGFR in Cancer Research · Oncology

h-index65

i10-index164

Publications442

Citations32,311

Grants

7 total · 0 active

NIH #5R21CA150166-02

Towards identification of prognostic gene sets in breast cancer: The E2197 Trial

Amount: $163K
Period: 2010-07-15 → 2012-06-30
PIs: 1
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #1R21CA150166-01

Towards identification of prognostic gene sets in breast cancer: The E2197 Trial

Amount: $211K
Period: 2010-07-15 → 2012-06-30
PIs: 1
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #1P30CA138292-01

DEVELOPMENTAL FUNDS

Amount: $134K
Period: 2009-04-07 → 2012-03-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last latest available · showing 20 of 27

Data from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Data from Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown PrimaryPreprint
2023-03-31
Tables S1-4, Figures S1-6 from Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown PrimaryPreprint
2023-03-31
Table S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Table S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Data from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Data from Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown PrimaryPreprint
2023-03-31
Tables S1-4, Figures S1-6 from Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown PrimaryPreprint
2023-03-31
Supplementary Material Legend from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Table S4 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Figure S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Table S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Table S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Table S3 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Figure S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Figure S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Table S4 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Table S3 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Supplementary Material Legend from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31
Figure S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast CancerPreprint
2023-03-31

Open author page on OpenAlex →

Brian Leyland‐Jones

Grants

Towards identification of prognostic gene sets in breast cancer: The E2197 Trial

Towards identification of prognostic gene sets in breast cancer: The E2197 Trial

DEVELOPMENTAL FUNDS

All Grants

Towards identification of prognostic gene sets in breast cancer: The E2197 Trial

Towards identification of prognostic gene sets in breast cancer: The E2197 Trial

DEVELOPMENTAL FUNDS

Prognostic and predictive gene sets in HER2-positive breast cancer:The HERA Trial

Prognostic and predictive gene sets in HER2-positive breast cancer:The HERA Trial

CANCER AND LEUKEMIA GROUP B

DATA SAFETY MONITORING PLAN

Career Trajectory

Research Cluster Map

Potential Collaborators

Recent Publications